In this regard, many biomarkers including PD-L1 expression, Tumor Mutational Burden (TMB) and DPMs frequent genetic alterations (like BAP1, TP53 and NF2) were explored but none reached a sufficient performance [11, 15, 16, 50–52], Currently, histology stands as the most important determinant for ICIs efficacy. This evidence concerns the gene TP53 and neoplasm.